意大利考虑对辉瑞未按约交付足额新冠疫苗采取法律行动
《路透》报道,意大利新冠特别专员Domenico Arcuri表示,正考虑就美国辉瑞药厂(Pfizer)(PFE.US)削减新冠疫苗供应采取法律行动。他指辉瑞上周削减向该国交付29%疫苗,本周二(19日)表示无法在下周补交剂量,并计划进一步减少交付。他称意大利政府内部经讨论後,已一致同意在未来数日采取行动,以保障公民及公众健康,包括循民事及刑事提控。
报道亦引述消息指,意大利政府正检视辉瑞无法依约供应疫苗是否基於不可控制因素,若发现辉瑞蓄意减少供货,便等同违反与欧盟签署的合约。其中一项可能做法是要求欧盟在比利时布鲁塞尔的法庭兴讼。欧盟成员国的疫苗订购由欧盟代表签署。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.